Overview Dividends

(KURA) Kura Oncology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US50127T1097

Ziftomenib, Tipifarnib, KO-2806

KURA EPS (Earnings per Share)

EPS (Earnings per Share) of KURA over the last years for every Quarter: "2020-09-30": -0.42, "2020-12-31": -0.45, "2021-03-31": -0.46, "2021-06-30": -0.51, "2021-09-30": -0.5, "2021-12-31": -0.49, "2022-03-31": -0.49, "2022-06-30": -0.52, "2022-09-30": -0.53, "2022-12-31": -0.49, "2023-03-31": -0.5, "2023-06-30": -0.53, "2023-09-30": -0.5, "2023-12-31": -0.55, "2024-03-31": -0.59, "2024-06-30": -0.59, "2024-09-30": -0.63, "2024-12-31": -0.22, "2025-03-31": -0.66, "2025-06-30": -0.75,
EPS Growth (3Y CAGR): -44.60%
EPS Trend (3Y Correlation): -24.4%

KURA Revenue

Revenue of KURA over the last years for every Quarter: 2020-09-30: 0, 2020-12-31: 0, 2021-03-31: 0, 2021-06-30: 0, 2021-09-30: 0, 2021-12-31: 0, 2022-03-31: 0, 2022-06-30: 0, 2022-09-30: 0, 2022-12-31: 0, 2023-03-31: 0, 2023-06-30: 0, 2023-09-30: 0, 2023-12-31: 1.27, 2024-03-31: 0, 2024-06-30: 0, 2024-09-30: 0, 2024-12-31: 53.883, 2025-03-31: 14.108, 2025-06-30: 15.288,
Revenue Growth (3Y CAGR): 63.07%
Revenue Trend (3Y Correlation): 72.5%

Description: KURA Kura Oncology

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative cancer treatments. The companys pipeline includes promising candidates such as ziftomenib, a menin-KMT2A interaction inhibitor, and tipifarnib, a farnesyl transferase inhibitor, which are being evaluated for various types of leukemia and solid tumors. With strategic collaborations with Novartis, Kyowa Kirin, and Mirati Therapeutics, Kura Oncology is poised to advance its product candidates through clinical trials and potentially bring new therapies to market.

The companys lead product candidate, ziftomenib, has shown potential in treating genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Tipifarnib is being evaluated in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. KO-2806, a selective FTI, is being investigated for the treatment of solid tumors. These developments demonstrate the companys commitment to addressing the unmet medical needs of cancer patients.

Analyzing the , we observe that the stock has been trading near its 52-week low, with the last price at $5.73. The SMA20 and SMA50 are $6.28 and $6.18, respectively, indicating a short-term downtrend. However, the ATR of 0.34 (5.94%) suggests that the stock is experiencing relatively low volatility. Given the , the companys market cap is $536.76M, and the P/E is not available due to negative earnings. The P/E Forward is also not available, indicating that the companys future earnings are uncertain.

Based on the and , our forecast suggests that Kura Oncologys stock may experience a short-term bounce, potentially reaching the SMA20 at $6.28, if the company announces positive clinical trial results or secures a new collaboration. However, the long-term trend remains uncertain due to the companys negative earnings and the competitive landscape of the biotechnology industry. A potential catalyst for the stock could be the outcome of the ongoing clinical trials, particularly for ziftomenib and tipifarnib. If the company can demonstrate the efficacy and safety of its product candidates, it may attract the attention of investors and potentially drive the stock price higher.

KURA Stock Overview

Market Cap in USD 732m
Sub-Industry Biotechnology
IPO / Inception 2015-09-22

KURA Stock Ratings

Growth Rating -65.9%
Fundamental 42.2%
Dividend Rating -
Return 12m vs S&P 500 -66.3%
Analyst Rating 4.53 of 5

KURA Dividends

Currently no dividends paid

KURA Growth Ratios

Growth Correlation 3m 82.4%
Growth Correlation 12m -76.7%
Growth Correlation 5y -62.8%
CAGR 5y -13.14%
CAGR/Max DD 3y -0.17
CAGR/Mean DD 3y -0.44
Sharpe Ratio 12m -1.50
Alpha 0.05
Beta 0.520
Volatility 56.41%
Current Volume 1324.3k
Average Volume 20d 1610.9k
Stop Loss 7.7 (-7.8%)
Signal 0.33

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-197.2m TTM) > 0 and > 6% of Revenue (6% = 5.00m TTM)
FCFTA 0.18 (>2.0%) and ΔFCFTA 42.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 663.9% (prev 36.7k%; Δ -36.1kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.18 (>3.0%) and CFO 125.0m > Net Income -197.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 6.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (87.6m) change vs 12m ago 1.10% (target <= -2.0% for YES)
Gross Margin 99.24% (prev 31.81%; Δ 67.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 13.91% (prev 0.25%; Δ 13.66pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -126.7 (EBITDA TTM -207.7m / Interest Expense TTM 1.59m) >= 6 (WARN >= 3)

Altman Z'' -4.65

(A) 0.81 = (Total Current Assets 660.1m - Total Current Liabilities 107.2m) / Total Assets 682.4m
(B) -1.49 = Retained Earnings (Balance) -1.02b / Total Assets 682.4m
warn (B) unusual magnitude: -1.49 — check mapping/units
(C) -0.34 = EBIT TTM -201.3m / Avg Total Assets 598.8m
(D) -2.70 = Book Value of Equity -1.02b / Total Liabilities 376.9m
Total Rating: -4.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.21

1. Piotroski 3.0pt = -2.0
2. FCF Yield 109.4% = 5.0
3. FCF Margin data missing
4. Debt/Equity 0.04 = 2.50
5. Debt/Ebitda -0.05 = -2.50
6. ROIC - WACC (= -59.94)% = -12.50
7. RoE -52.32% = -2.50
8. Rev. Trend 72.50% = 5.44
9. EPS Trend -24.44% = -1.22

What is the price of KURA shares?

As of September 17, 2025, the stock is trading at USD 8.35 with a total of 1,324,337 shares traded.
Over the past week, the price has changed by +4.24%, over one month by +11.63%, over three months by +28.66% and over the past year by -59.99%.

Is Kura Oncology a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Kura Oncology (NASDAQ:KURA) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 42.21 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KURA is around 7.06 USD . This means that KURA is currently overvalued and has a potential downside of -15.45%.

Is KURA a buy, sell or hold?

Kura Oncology has received a consensus analysts rating of 4.53. Therefore, it is recommended to buy KURA.
  • Strong Buy: 10
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the KURA price?

Issuer Target Up/Down from current
Wallstreet Target Price 27 223.4%
Analysts Target Price 27 223.4%
ValueRay Target Price 7.8 -6.1%

Last update: 2025-09-05 04:50

KURA Fundamental Data Overview

Market Cap USD = 731.7m (731.7m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 630.7m USD (Cash And Short Term Investments, last quarter)
P/S = 8.7861
P/B = 2.3938
Beta = 0.403
Revenue TTM = 83.3m USD
EBIT TTM = -201.3m USD
EBITDA TTM = -207.7m USD
Long Term Debt = 6.51m USD (from longTermDebt, last quarter)
Short Term Debt = 4.81m USD (from shortTermDebt, last quarter)
Debt = 11.3m USD (Calculated: Short Term 4.81m + Long Term 6.51m)
Net Debt = -69.0m USD (from netDebt column, last quarter)
Enterprise Value = 112.3m USD (731.7m + Debt 11.3m - CCE 630.7m)
Interest Coverage Ratio = -126.7 (Ebit TTM -201.3m / Interest Expense TTM 1.59m)
FCF Yield = 109.4% (FCF TTM 122.9m / Enterprise Value 112.3m)
FCF Margin = 147.5% (FCF TTM 122.9m / Revenue TTM 83.3m)
Net Margin = -236.8% (Net Income TTM -197.2m / Revenue TTM 83.3m)
Gross Margin = 99.24% ((Revenue TTM 83.3m - Cost of Revenue TTM 636.0k) / Revenue TTM)
Tobins Q-Ratio = -0.11 (set to none) (Enterprise Value 112.3m / Book Value Of Equity -1.02b)
Interest Expense / Debt = 3.45% (Interest Expense 391.0k / Debt 11.3m)
Taxrate = 21.0% (US default)
NOPAT = -201.3m (EBIT -201.3m, no tax applied on loss)
Current Ratio = 6.16 (Total Current Assets 660.1m / Total Current Liabilities 107.2m)
Debt / Equity = 0.04 (Debt 11.3m / last Quarter total Stockholder Equity 305.5m)
Debt / EBITDA = -0.05 (Net Debt -69.0m / EBITDA -207.7m)
Debt / FCF = 0.09 (Debt 11.3m / FCF TTM 122.9m)
Total Stockholder Equity = 376.8m (last 4 quarters mean)
RoA = -28.89% (Net Income -197.2m, Total Assets 682.4m )
RoE = -52.32% (Net Income TTM -197.2m / Total Stockholder Equity 376.8m)
RoCE = -52.50% (Ebit -201.3m / (Equity 376.8m + L.T.Debt 6.51m))
RoIC = -52.09% (NOPAT -201.3m / Invested Capital 386.4m)
WACC = 7.85% (E(731.7m)/V(743.0m) * Re(7.93%)) + (D(11.3m)/V(743.0m) * Rd(3.45%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 2.48%
Discount Rate = 7.93% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 79.02% ; FCFE base≈122.9m ; Y1≈129.3m ; Y5≈152.1m
Fair Price DCF = 30.71 (DCF Value 2.67b / Shares Outstanding 86.8m; 5y FCF grow 5.73% → 3.0% )
EPS Correlation: -24.44 | EPS CAGR: -44.60% | SUE: -2.24 | # QB: 0
Revenue Correlation: 72.50 | Revenue CAGR: 63.07% | SUE: N/A | # QB: None

Additional Sources for KURA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle